Patients with HER2+ breast cancer who develop resistance to trastuzumab may soon have an alternative therapy, according to recent findings published in Clinical Cancer Research.
Tissue velocity imaging and strain imaging can predict preclinical changes in left ventricular (LV) systolic function before a patient experiences a change in left ventricular ejection fraction (LVEF), according to a prospective study in HER2-positive patients receiving trastuzumab in the adjuvant setting. Cardiac biomarkers, however, did not predict the development of cardiac dysfunction. Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
